Pharma News

Shilpa Biologicals Private Limited, SBPL, has entered into a 3 year DefInitive Agreement with Dr. Reddys Laboratories Limited, DRL, for production supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka.

American India Foundation (AIF), on Thursday confirmed, that in collaboration with Paytm, Indian Biogas Association, Foundation For Innovation & Research In Science & Technology and Acquafront Infrastructure Pvt. Ltd., it is set to roll out Oxygen Plants in 25 of the most virus-ravaged cities in the country.

Dr. Reddys Laboratories Ltd announced that it has entered into a royalty-free, non-exclusive voluntary  licensing agreement with  Eli Lilly and Company for the manufacture and commercialization of the drug, baricitinib,in India.

Zydus Animal Health and Investments Limited  a wholly owned material subsidiary of Cadila Healthcare Limited, has entered into a Business Transfer Agreement (BTA) and other Ancillary Agreements  to sell and transfer its Animal Healthcare Established Markets Undertaking to Multiples Alternate Asset Management led consortium. Zydus AH is the animal health business of ZAHL focused on India and certain other countries.

Dr. Reddys Laboratories Ltd announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and Drug Administration (USFDA).

The Karnataka government served notices to pharmaceutical majors Cipla and Jubilant warning them of legal proceedings for not supplying adequate quantities of Remdesivir injection bottles as directed by the Government of India. In a notice to the pharmaceutical companies, the Principal Secretary in the Revenue department N Manjunatha Prasad said they were ordered to deliver 62,000 vials of Remdesivir injection, but they supplied very less consignment.

A sudden increase in demand has been observed in some states for Amphotericin B which is being actively prescribed by the physicians to patients suffering from Mucormycosis, a post COVID complication. The Government of India is therefore engaging with the manufacturers to ramp up production of the drug. The supply position is expected to improve with extra  imports of this drug and  increase in its production domestically.

BioArctic AB announced today that the Japanese Patent Office (JPO) has allowed the company’s Japanese patent application 2017-083057 for novel antibodies that could be developed into a treatment for Alzheimers disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aβ) and are linked to the company’s project AD1503. BioArctic received a patent in Europe based on the same antibodies in January 2021.

To recognize the phenomenal contribution of nurses to the healthcare delivery system across the world, Aster DM Healthcare has launched the Aster Guardian Global Nursing Award. This is all the more relevant in the current scenario as they continue to play a pivotal role in delivering care despite the challenges produced by the Covid-19 pandemic, taking care of patients worldwide and risking their lives.